On World Cancer Day, Adalvo highlights its commitment to expanding access to high-quality oncology treatments. With a portfolio of 37 INNs and a total addressable market of $58 billion (according to IQVIA), we continue to strengthen our impact in cancer care, ensuring broader access to differentiated therapies.
Recent additions to our portfolio include Apalutamide, Binimetinib, Cabozantinib, Ribociclib. Venetoclax, and Vismodegib Tablets.
Our oncology launches highlight our ability to deliver high-impact solutions quickly and effectively. Milestones include:
DCPs are in progress for Azacitidine, Palbociclib, and Afatinib, while approved therapies such as Nintedanib Soft Gel Capsules, Ibrutinib Capsules, and Bosutinib Tablets will continue to provide treatment options across Europe.
To address patient-specific needs, Adalvo is also developing added-value products, such as our Lenvatinib Oral Liquid Formulation to improve treatment adherence, usability, and offer tailored treatment options.
Click here to ask about viewing our oncology portfolio!
At Adalvo, there are no half-measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
Partner Up Now